This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.
Patients able to give written informed consent;
Age ≥ 18 and ≤ 75 years old, male or female;
Patients have histological or cytological diagnosis with advanced solid tumors.
Have measurable lesions defined in RECIST v. 1.1;
Have had other malignant tumors in the past 5 years;
Have CNS (central nervous system) metastasis with clinical symptoms;
Had undergone major surgery or severe trauma within 4 weeks prior to the first dose;
Had undergone systemic high-dose steroids within 2 weeks of initiation of study treatment;